Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN SODIUM versus CEFOBID IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN SODIUM versus CEFOBID IN PLASTIC CONTAINER.
CEFAZOLIN SODIUM vs CEFOBID IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1a, PBP1b, PBP2a, PBP2b, PBP2x, PBP3, and PBP4, thereby preventing cross-linking of peptidoglycan chains. This leads to cell lysis and death.
Cefoperazone, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
1-2 g IV/IM every 8 hours; maximum 12 g/day for severe infections.
2 g IV every 8-12 hours; usual total daily dose 4-6 g, severe infections up to 12 g daily divided q8h.
None Documented
None Documented
Approximately 1.8 hours (range 1.2-2.2 h) in normal renal function; prolonged in renal impairment (up to 30-40 h in ESRD)
2.2 hours (normal renal function); prolonged to 4-5 hours in elderly or hepatic impairment; in severe renal failure (CrCl <10 mL/min), may extend up to 8 hours.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); minimal biliary (1-2%); fecal (<1%)
Renal: 65-85% unchanged; biliary: 10-20% (fecal elimination); total renal clearance approximates glomerular filtration rate.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic